Michael Sundstrom received his PhD from Uppsala, followed by PostDoctoral studies at Karolinska Institute. From 1993-2000 he was at Pharmacia as Director for structure-based drug design and oncology R&D portfolio management. Between 2001 and 2003 he held senior positions at the Swedish Biotechs Actar and Biovitrum. In 2003 he joined the Structural Genomics Consortium (SGC) at the University of Oxford, as Chief Scientist. In 2007 he assumed the position as Managing Director for the Novo Nordisk Foundation Center for Protein Research (Copenhagen). From end of 2011, he was VP Discovery Research at Karolinska Development. He then re-joined the SGC and Karolinska Institutet and is since mid-2014 as Scientific Director for the SGC at KI.

Current Duties

Michael has three main research responsibilities 1) member of the global research leadership team coordinating projects and activities of common interest within the consortium; 2) site head for SGC Karolinska and 3) main scientific focus and responsibility for the SGC Tissue Platforms at Karolinska, Oxford and Montreal; working to establish high quality cell-based assays using patient-derived cell systems in inflammation and neurodegenerative diseases. The research activities carried out at the laboratory are focused on translational assays and target validation in systemic auto-immune diseases and inflammatory bowel diseases, as well as the generation of high quality recombinant antibodies.


Team leader

Michael Sundström


Job title

Senior lab manager